1. Search Result
Search Result
Results for "

progression

" in MedChemExpress (MCE) Product Catalog:

265

Inhibitors & Agonists

14

Screening Libraries

1

Fluorescent Dye

1

Biochemical Assay Reagents

11

Peptides

4

Inhibitory Antibodies

27

Natural
Products

7

Isotope-Labeled Compounds

11

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145759

    MDM-2/p53 Cancer
    Mutant p53 modulator-1 is a mutant p53 modulator. Mutant p53 modulator-1 reduces the progression of cancers that contain a p53 mutation (extracted from patent WO2021231474A1, compound 231B) .
    Mutant p53 modulator-1
  • HY-107637

    MMP Cardiovascular Disease
    ONO-4817 is a potent inhibitor of matrix metalloproteinase (MMP). Inhibition of matrix metalloproteinases (MMPs) is expected to suppress atherosclerotic neointimal proliferation and thus limits atheromatous plaque progression. ONO-4817 suppresses the development of aortic intimal hyperplasia in experimental hyperlipidemic rabbit .
    ONO-4817
  • HY-146667

    Others Neurological Disease Cancer
    POP-IN-1 (Compound 12h) is a potent inhibitor of POP with an Ki of 0.009 μM. POP-IN-1 has the potential for the research of neurodegenerative diseases and cancer progression .
    POP-IN-1
  • HY-156792

    Others Cancer
    RIOK2-IN-1 (com 4) is a potent and selective RIOK2 inhibitor (Kd=150 nM), but has low cellular activity (IC50=14,600 nM). RIOK2 is an atypical kinase associated with a variety of human cancers and is involved in ribosome maturation and cell cycle progression. The small molecule inhibitor CQ211 (HY-147655), an improvement of RIOK2-IN-1 as the lead compound, has good in vivo and in vitro activity, inhibits the proliferation of MKN-1 and HT-29 cancer cells, and can xenograft MKN in mice -1 model inhibits tumor progression .
    RIOK2-IN-1
  • HY-119711

    MMP Cancer
    NNGH is a stromelysin-1 (MMP-3) inhibitor. MMP-3 is both a direct transcriptional target and a necessary contributor of the Wnt/β-catenin signaling pathway. Matrix metalloproteinases (MMPs) play a well-defined role in later stages of tumor progression .
    NNGH
  • HY-142931

    ATM/ATR Neurological Disease Cancer
    ATM-IN-1 is a potent inhibitor of ATM. ATM is located mainly in the nucleus and microsomes and is involved in cell cycle progression and in the cell cycle checkpoint response to DNA damage. ATM-IN-1 has the potential for the research of cancer and neurology diseases (extracted from patent WO2021139814A1, compound 3) .
    ATM-IN-1
  • HY-120793

    TRB-N0224

    Ras Apoptosis MMP Inflammation/Immunology Cancer
    CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibiting Ras activation and its downstream effector ERK1/2 pathway. CMC2.24 is also a potent inhibitor of zinc-dependent MMPs with IC50s ranging from 2.0-69 μM. CMC2.24 alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis .
    CMC2.24
  • HY-143660

    Microtubule/Tubulin Apoptosis Cancer
    LG308 is a novel synthetic compound with antimicrotubule activity. LG308 induces mitotic phase arrest and inhibits G2/M progression significantly which is associated with the upregulation of cyclin B1 and mitotic marker MPM-2 and the dephosphorylation of cdc2. LG308 also induces apoptosis and cell death. LG308 significantly suppresses tumor growth. LG308 with antimitotic activity has the potential for the research of prostate cancer .
    LG308
  • HY-113057

    Endogenous Metabolite Cancer
    3-Hydroxycapric acid is an inhibitor for mitotic progression.
    3-Hydroxycapric acid
  • HY-142870

    Others Cancer
    ZY-444 is a small molecule that suppresses breast cancer progression by targeting pyruvate carboxylase.
    ZY-444
  • HY-131959

    E3 Ligase Ligand-Linker Conjugates Cancer
    (S,R,S)-AHPC-PEG5-Boc is a E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for Cdc20 degrader CP5V .
    (S,R,S)-AHPC-PEG5-Boc
  • HY-B0191

    AGN 192024

    Prostaglandin Receptor Endocrinology
    Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.
    Bimatoprost
  • HY-P1572

    Renin Inflammation/Immunology
    Handle region peptide, rat is a prorenin receptor antagonist, suppresses the progression of diabetic nephropathy and has anti-inflammatory in the eye.
    Handle region peptide, rat
  • HY-W088191

    Others Cardiovascular Disease
    4-Hydroxybenzamide, found in the herb of Berberis pruinosa, is a known natural product that has potential to slow down the progression of atherosclerosis .
    4-Hydroxybenzamide
  • HY-117962A

    Guanylate Cyclase Metabolic Disease
    BI 703704 is a potent soluble guanylate cyclase (sGC) activator. BI 703704 inhibits the progression of diabetic nephropathy in the ZSF1 rat .
    BI 703704
  • HY-100670

    Epigenetic Reader Domain Neurological Disease
    Olinone is a selective BRD4 BrD1 inhibitor . Olinone accelerates the progression of mouse primary oligodendrocyte progenitors toward differentiation .
    Olinone
  • HY-124557

    Others Metabolic Disease Inflammation/Immunology
    Mahanimbine is an orally active alkaloid from Murraya koenigii. Mahanimbine inhibits progression of high-fat diet (HFD)-induced metabolic complications in mice .
    Mahanimbine
  • HY-116582

    NO Synthase Infection Inflammation/Immunology Cancer
    8-Nitroguanine, a product of nitrative DNA damage caused by reactive nitrogen species, is a potential biomarker for progression of malignant fibrous histiocytoma .
    8-Nitroguanine
  • HY-B0191S1

    AGN 192024-d4

    Prostaglandin Receptor Endocrinology
    Bimatoprost-d4 is the deuterium labeled Bimatoprost. Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.
    Bimatoprost-d4
  • HY-147361

    Apoptosis Lactate Dehydrogenase Cancer
    LDCA is a dual-hit metabolic modulator and inhibits LDH-A enzyme activity to stimulate apoptosis in the malignant population. LDCA can be used for the research of oncogenic progression .
    LDCA
  • HY-N10394

    Others Cancer
    Metachromins X is a sesquiterpene quinone that arrests the cell cycle progression of HeLa/Fucci2 cells at S/G2/M phase .
    Metachromins X
  • HY-163129

    Apoptosis MMP Cancer
    BPU arrests cell cycle progression in the sub-G1 phase. BPU is an anticancer agent through inhibiting blood vessel formation in tumor tissues .
    BPU
  • HY-N6985

    Others Cancer
    Baccatin III is a natural product isolated from Pacific yew tree and related species. Baccatin III reduces tumor progression by inhibiting the accumulation and suppressive function of MDSCs .
    Baccatin III
  • HY-133558

    E1/E2/E3 Enzyme Apoptosis Cancer
    VII-31 is a potent NEDDylation pathway activator to inhibit the tumor progression in vitro and in vivo. VII-31 induces apoptosis via intrinsic and extrinsic pathways .
    VII-31
  • HY-116894

    Apoptosis Cancer
    Rotundifuran, a labdane type diterpene, is isolated from Vitex rotundifolia. Rotundifuran can inhibit the cell cycle progression and induce apoptosis in human myeloid leukaemia cells .
    Rotundifuran
  • HY-119518

    BMS-209641

    RAR/RXR Cancer
    BMS641 (BMS-209641) is a selective RARβ agonist. BMS641 has a higher affinity for RARβ (Kd, 2.5 nM) that is 100 times higher than that for RARα (Kd, 225 nM) or RARγ (Kd, 223 nM) .
    BMS641
  • HY-120499

    Hedgehog Smo Cancer
    AZD8542 is an antagonist of Smoothened (SMO), playing an important role in oncology. AZD8542 is a? Hedgehog (Hh) pathway antagonist on tumor progression with an emphasis on the role of the stroma compartment .
    AZD8542
  • HY-13555
    β-Lapachone
    5+ Cited Publications

    ARQ-501; NSC-26326

    Topoisomerase Autophagy Apoptosis Cancer
    β-Lapachone (ARQ-501;NSC-26326) is a naturally occurring O-naphthoquinone, acts as a topoisomerase I inhibitor, and induces apoptosis by inhibiting cell cycle progression.
    β-Lapachone
  • HY-100599
    Urolithin A
    Maximum Cited Publications
    16 Publications Verification

    Drug Metabolite Reactive Oxygen Species DNA/RNA Synthesis Autophagy Apoptosis Endogenous Metabolite Cancer
    Urolithin A, a gut-microbial metabolite of ellagic acid, exerts anti-inflammatory, antiproliferative, and antioxidant properties. Urolithin A induces autophagy and apoptosis, suppresses cell cycle progression, and inhibits DNA synthesis .
    Urolithin A
  • HY-14804A

    LY 573636 sodium

    Apoptosis Cancer
    Tasisulam is a anticancer agent and induces apoptosis via the intrinsic pathway, resulting in cytochrome c release and caspase-dependent cell death. Tasisulam inhibits mitotic progression and induces vascular normalization .
    Tasisulam sodium
  • HY-14804

    LY 573636

    Molecular Glues Apoptosis Cancer
    Tasisulam is a anticancer agent and induces apoptosis via the intrinsic pathway, resulting in cytochrome c release and caspase-dependent cell death. Tasisulam inhibits mitotic progression and induces vascular normalization .
    Tasisulam
  • HY-122381

    Bacterial Endogenous Metabolite Neurological Disease
    Kyotorphin is an endogenou neuroactive dipeptide with analgesic properties. Kyotorphin possesses anti-inflammatory and antimicrobial activity. Kyotorphin levels in cerebro-spinal fluid correlate negatively with the progression of neurodegeneration in Alzheimer's Disease patients .
    Kyotorphin
  • HY-153833

    KVA-E-23A

    Others Cancer
    PDS-0330 is a specific and potent Claudin-1 inhibitor. PDS-0330 interferes with claudin-1/Src association and inhibits colorectal cancer (CRC) progression and metastasis .
    PDS-0330
  • HY-156430

    MMP Cancer
    MMP-7-IN-3 is a potent and selective inhibitor of MMP-7. MMP-7-IN-3 suppresses kidney fibrosis progression in a mouse model with unilateral ureteral obstruction .
    MMP-7-IN-3
  • HY-117962

    Guanylate Cyclase Metabolic Disease
    (Rac)-BI 703704 is a potent soluble guanylyl cyclase (sGC) activator. (Rac)-BI 703704 reduces progression of renal damage in the ZSF1 rat, and highlight the potential of sGC activation as an effective therapy for diabetic nephropathy .
    (Rac)-BI 703704
  • HY-137655

    Protein Arginine Deiminase Cancer
    BMS-P5 is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model .
    BMS-P5
  • HY-122506

    STAT Cancer
    Salviolone is a natural diterpenoid derivative that can against melanoma cells. Salviolone exhibits a pleiotropic effect against melanoma by hampering cell cycle progression, STAT3 signaling, and malignant phenotype of A375 melanoma cells .
    Salviolone
  • HY-156979

    SARS-CoV HCV Infection
    RBT-9 prevents progression to severe COVID-19 and organ failure. RBT-9 also has antiviral effects, as demonstrated in several enveloped viruses, including influenza, HCV, dengue, and yellow fever .
    RBT-9
  • HY-144117A

    CDK Neurological Disease Cancer
    (S)-GFB-12811 (compound 596) is a potent and selective CDK5 inhibitor, with an IC50 value less than 10 nM. (S)-GFB-12811 can be used in the research of cell cycle progression, neuronal development, tumorigenesis .
    (S)-GFB-12811
  • HY-P99817

    Interleukin Related HIV Infection
    Pegaldesleukin is a conjugate of polyethylene glycol and interleukin-2 (PEG-IL2). Pegaldeslukin has antiviral activity and has potential applications in HIV, possibly delaying the progression of HIV infection by retaining the immune repertoire .
    Pegaldesleukin
  • HY-117365

    Others Cancer
    MI-1481 is a highly potent inhibitor of the Menin-MLL1 interaction with IC50 of 3.6 nM. MI-1481 markedly reduces cell growth of murine bone marrow cells transformed and inhibits leukemia progression .
    MI-1481
  • HY-126114
    Lupeol acetate
    1 Publications Verification

    COX Interleukin Related Inflammation/Immunology
    Lupeol acetate, a derivative of Lupeol, suppresses the progression of rheumatoid arthritis (RA) by inhibiting the activation of macrophages and osteoclastogenesis through downregulations of TNF-α, IL-1β, MCP-1, COX-2, VEGF and granzyme B .
    Lupeol acetate
  • HY-137655A

    Protein Arginine Deiminase Cancer
    BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor. BMS-P5 free base blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model .
    BMS-P5 free base
  • HY-13706A

    TM30089

    Prostaglandin Receptor Inflammation/Immunology
    CAY10471 (TM30089) is a potent, selective, and orally active prostaglandin D2 receptor CRTH2 antagonist. CAY10471 attenuates the progression of tubulointerstitial fibrosis and chronic contact hypersensitivity (CHS) in animal model .
    CAY10471
  • HY-149482

    Cathepsin Cancer
    LN5P45 is an OTUB2 inhibitor (IC50: 2.3 μM). LN5P45 induces monoubiquitination of OTUB2 on lysine 31. LN5P45 can be used for research of tumor progression and metastasis .
    LN5P45
  • HY-131651

    LTB4 ethanolamide

    Endogenous Metabolite Leukotriene Receptor Cancer
    Leukotriene B4 ethanolamide (LTB4 ethanolamide) is an antagonist and a partial agonist for Leukotriene B4 (LTB4) receptor 1 (BLTR1). Leukotriene B4 ethanolamide ameliorates the tumor progression, which is only asscociated with inflammation .
    Leukotriene B4 ethanolamide
  • HY-N3913

    STAT Bcl-2 Family Cancer
    Furowanin A is a flavonoid with anti-neoplastic effects. Furowanin A inhibits STAT3/Mcl-1 axis to suppress proliferation, block cell cycle progression, induce apoptosis and promote autophagy. Furowanin A potently inhibits colorectal cancer (CRC) cells .
    Furowanin A
  • HY-32015
    Cot inhibitor-1
    2 Publications Verification

    MAP3K Inflammation/Immunology
    Cot inhibitor-1 (compound 28) is a selective tumor progression loci-2 (Tpl2) kinase inhibitor with an IC50 of 28 nM. Cot inhibitor-1 shows an inhibition of TNF-alpha production in human whole blood with an IC50 of 5.7 nM .
    Cot inhibitor-1
  • HY-50682
    Azeliragon
    5+ Cited Publications

    TTP488; PF-04494700

    Amyloid-β Neurological Disease
    Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .
    Azeliragon
  • HY-128849

    Others Inflammation/Immunology
    Eprodisate is a new compound designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues . Eprodisate slow the progression of AA amyloidosis-related renal disease and has possible applicability to other types of amyloidosis .
    Eprodisate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: